secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xenetic Biosciences, Inc. (XBIO)
CIK:        0001534525
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0001683168-23-003203
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xenetic Biosciences Q1 net loss $0.9M; cash $12M; Takeda royalties up 55.7%
---------------------------------------------------------------------------

- Net loss of $0.9M for Q1 2023; R&D expenses down 46% to $0.6M from $1.1M.
- Royalty payments from Takeda sublicense increased 55.7% to $0.6M.
- Ended quarter with $12.0M cash; advancing DNase oncology program.
- Entered collaboration with Scripps Research Institute for DNase and CAR T programs.
- Appointed Scott N. Cullison and Reid P. Bissonnette to support DNase platform.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534525/000168316823003203/0001683168-23-003203-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534525/000168316823003203/xenetic_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-23-003203

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer